Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $227.07

Shares of Biogen Inc. (NASDAQ:BIIB) have received a consensus recommendation of “Moderate Buy” from the thirty-three research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, eighteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $227.7857.

Several equities research analysts have weighed in on the company. Citigroup upped their price target on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Bank of America decreased their price objective on Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research note on Tuesday, July 21st. Truist Financial raised Biogen from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. TD Cowen boosted their price objective on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th.

Biogen Stock Performance

NASDAQ:BIIB opened at $220.77 on Friday. The company has a fifty day simple moving average of $206.42 and a two-hundred day simple moving average of $195.12. The company has a market cap of $32.62 billion, a price-to-earnings ratio of 39.07, a price-to-earnings-growth ratio of 6.80 and a beta of 0.17. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 52 week low of $131.52 and a 52 week high of $222.85.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company’s revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts anticipate that Biogen will post 12.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biogen

A number of large investors have recently modified their holdings of the company. Reflection Asset Management purchased a new stake in shares of Biogen during the 4th quarter worth $25,000. WPG Advisers LLC increased its holdings in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the last quarter. Bell Investment Advisors Inc purchased a new position in Biogen in the second quarter valued at $27,000. First Horizon Corp acquired a new stake in Biogen in the fourth quarter valued at $30,000. Finally, WFA of San Diego LLC acquired a new stake in Biogen in the second quarter valued at $32,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.